|
1
|
Isaac MG, Quinn R and Tabet N: Vitamin E
for Alzheimer's disease and mild cognitive impairment. Cochrane
Database Syst Rev. 3:CD0028542008.
|
|
2
|
Association A: Alzheimer's Association:
2012 Alzheimer's disease facts and figures. Alzheimers Dement.
8:131–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Querfurth HW and LaFerla FM: Alzheimer's
disease. N Engl J Med. 362:329–344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hardy J and Selkoe DJ: The amyloid
hypothesis of Alzheimer's disease: Progress and problems on the
road to therapeutics. Science. 297:353–356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seshadri S, Beiser A, Selhub J, Jacques
PF, Rosenberg IH, D'Agostino RB, Wilson PW and Wolf PA: Plasma
homocysteine as a risk factor for dementia and Alzheimer's disease.
N Engl J Med. 346:476–483. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Musiał A, Bajda M and Malawska B: Recent
developments in cholinesterases inhibitors for Alzheimer's disease
treatment. Curr Med Chem. 14:2654–2679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ingrosso D, Cimmino A, Perna AF, Masella
L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M,
Galletti P, et al: Folate treatment and unbalanced methylation and
changes of allelic expression induced by hyperhomocysteinaemia in
patients with uraemia. Lancet. 361:1693–1699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhuo JM, Wang H and Praticò D: Is
hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD
marker, or neither? Trends Pharmacol Sci. 32:562–571. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pandey SN, Vaidya AD, Vaidya RA and
Talwalkar S: Hyperhomocysteinemia as a cardiovascular risk factor
in Indian women: Determinants and directionality. J Assoc
Physicians India. 54:769–774. 2006.PubMed/NCBI
|
|
10
|
Fernandez HH, Friedman JH, Grace J and
Beason-Hazen S: Donepezil for Huntington's disease. Mov Disord.
15:173–176. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mazza M, Capuano A, Bria P and Mazza S:
Ginkgo biloba and donepezil: A comparison in the treatment of
Alzheimer's dementia in a randomized placebo-controlled
double-blind study. Eur J Neurol. 13:981–985. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sam RC, Burns PJ, Hobbs SD, Marshall T,
Wilmink AB, Silverman SH and Bradbury AW: The prevalence of
hyperhomocysteinemia, methylene tetrahydrofolate reductase C677T
mutation, and vitamin B12 and folate deficiency in patients with
chronic venous insufficiency. J Vasc Surg. 38:904–908. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varma AR, Snowden JS, Lloyd JJ, Talbot PR,
Mann DM and Neary D: Evaluation of the NINCDS-ADRDA criteria in the
differentiation of Alzheimer's disease and frontotemporal dementia.
J Neurol Neurosurg Psychiatry. 66:184–188. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cole JC, Motivala SJ, Buysse DJ, Oxman MN,
Levin MJ and Irwin MR: Validation of a 3-factor scoring model for
the Pittsburgh sleep quality index in older adults. Sleep.
29:112–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harrington CR: The molecular pathology of
Alzheimer's disease. Neuroimaging Clin N Am. 2211–22. (vii)2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Minoshima S, Giordani B, Berent S, Frey
KA, Foster NL and Kuhl DE: Metabolic reduction in the posterior
cingulate cortex in very early Alzheimer's disease. Ann Neurol.
42:85–94. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Doody RS, Demirovic J, Ballantyne CM, Chan
W, Barber R, Powell S and Pavlik V: Texas Alzheimer's Disease
Research and Care Consortium: Lipoprotein-associated phospholipase
A2, homocysteine, and Alzheimer's disease. Alzheimers Dement
(Amst). 1:464–471. 2015.PubMed/NCBI
|
|
18
|
Van Dam F and Van Gool WA:
Hyperhomocysteinemia and Alzheimer's disease: A systematic review.
Arch Gerontol Geriatr. 48:425–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feldman H, Gauthier S, Hecker J, Vellas B,
Subbiah P and Whalen E: Donepezil MSAD Study Investigators Group: A
24-week, randomized, double-blind study of donepezil in moderate to
severe Alzheimer's disease. Neurology. 57:613–620. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qian S, He L, Mak M, Han Y, Ho CY and Zuo
Z: Synthesis, biological activity, and biopharmaceutical
characterization of tacrine dimers as acetylcholinesterase
inhibitors. Int J Pharm. 477:442–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Werder SF: Cobalamin deficiency,
hyperhomocysteinemia, and dementia. Neuropsychiatr Dis Treat.
6:159–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nabi H, Bochud M, Glaus J, Lasserre AM,
Waeber G, Vollenweider P and Preisig M: Association of serum
homocysteine with major depressive disorder: Results from a large
population-based study. Psychoneuroendocrinology. 38:2309–2318.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lominadze D, Tyagi N, Sen U, Ovechkin A
and Tyagi SC: Homocysteine alters cerebral microvascular integrity
and causes remodeling by antagonizing GABA-A receptor. Mol Cell
Biochem. 371:89–96. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dietrich-Muszalska A, Malinowska J, Olas
B, Głowacki R, Bald E, Wachowicz B and Rabe-Jabłońska J: The
oxidative stress may be induced by the elevated homocysteine in
schizophrenic patients. Neurochem Res. 37:1057–1062. 2012.
View Article : Google Scholar : PubMed/NCBI
|
